Table 3 Prescribed non-steroidal anti-inflammatory drugs and centrally acting agents. (*) means that the drug was discontinued at least 24 hrs before the study. Plasma half-life of each compound is also indicated.
From: Norepinephrine-evoked pain in fibromyalgia. A randomized pilot study ISCRTN70707830
| Fibromyalgia | Rheumatoid Arthritis | ||||
|---|---|---|---|---|---|
| Drug | Number of patients | Plasma half-life (hours) | Drug | Number of patients | Plasma half-life (hours) |
| clonazepam | 6 | 20–60 | acetaminophen* | 4 | 4–6 |
| acetaminophen* | 5 | 4–6 | celecoxib* | 3 | 10–12 |
| mianserin | 2 | 21–61 | diclofenac* | 3 | 3–7 |
| alprazolam | 2 | 12–15 | piroxicam* | 2 | 34–50 |
| bromazepam | 1 | 20 | clonazepam | 1 | 20–60 |
| triazolam | 1 | 1.5–5.5 | alprazolam | 1 | 12–15 |
| piroxicam* | 1 | 34–50 | indomethacin* | 1 | 4–5 |
| celecoxib* | 1 | 10–12 | aspirin* | 1 | 2–3 |
| ketoprofen* | 1 | 1.5–4 | rofecoxib* | 1 | 17 |
| fluoxetine | 1 | 96–144 | ibuprofen* | 1 | 2–3 |
| gabapentin* | 1 | 5–9 | gabapentin* | 1 | 5–9 |